Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
HMPL-306 by Hutchison MediPharma for Myelodysplastic Syndrome: Likelihood of Approval
HMPL-306 is under clinical development by Hutchison MediPharma and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase...
HMPL-306 by Hutchison MediPharma for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
HMPL-306 is under clinical development by Hutchison MediPharma and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Surufatinib by Hutchison MediPharma for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase III for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Surufatinib by Hutchison MediPharma for Metastatic Pancreatic Cancer: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase III for Metastatic Pancreatic Cancer. According to GlobalData,...
Surufatinib by Hutchison MediPharma for Ovarian Cancer: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Surufatinib by Hutchison MediPharma for Soft Tissue Sarcoma: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...
Surufatinib by Hutchison MediPharma for Solid Tumor: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Surufatinib by Hutchison MediPharma for Non-Rhabdomyosarcoma: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Non-Rhabdomyosarcoma. According to GlobalData, Phase II...
Surufatinib by Hutchison MediPharma for Rhabdomyosarcoma: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Rhabdomyosarcoma. According to GlobalData, Phase II...
Surufatinib by Hutchison MediPharma for Ewing Sarcoma: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Ewing Sarcoma. According to GlobalData, Phase...
Surufatinib by Hutchison MediPharma for Osteosarcoma: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II...
Surufatinib by Hutchison MediPharma for Lymphoma: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Lymphoma. According to GlobalData, Phase II...
HMPL-760 by Hutchison MediPharma for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
HMPL-760 is under clinical development by Hutchison MediPharma and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...
Sovleplenib acetate by Hutchison MediPharma for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Sovleplenib acetate is under clinical development by Hutchison MediPharma and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL)....
Sovleplenib acetate by Hutchison MediPharma for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura): Likelihood of Approval
Sovleplenib acetate is under clinical development by Hutchison MediPharma and currently in Phase I for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic...
Sovleplenib acetate by Hutchison MediPharma for Mantle Cell Lymphoma: Likelihood of Approval
Sovleplenib acetate is under clinical development by Hutchison MediPharma and currently in Phase I for Mantle Cell Lymphoma. According to...
Sovleplenib acetate by Hutchison MediPharma for Marginal Zone B-cell Lymphoma: Likelihood of Approval
Sovleplenib acetate is under clinical development by Hutchison MediPharma and currently in Phase I for Marginal Zone B-cell Lymphoma. According...
Sovleplenib acetate by Hutchison MediPharma for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
Sovleplenib acetate is under clinical development by Hutchison MediPharma and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According...
Surufatinib by Hutchison MediPharma for Epithelial Ovarian Cancer: Likelihood of Approval
Surufatinib is under clinical development by Hutchison MediPharma and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...
HMPL-306 by Hutchison MediPharma for Hematological Tumor: Likelihood of Approval
HMPL-306 is under clinical development by Hutchison MediPharma and currently in Phase I for Hematological Tumor. According to GlobalData, Phase...